Compare Carparts.Com Inc (PRTS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs TG Therapeutics Inc — how do they compare? Carparts.Com Inc trades at $8.63 (market cap $66.42M), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 122.9× Carparts.Com Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and TG Therapeutics Inc for 16 Days on average.
| PRTS | TGTX | |
|---|---|---|
Market Cap | $66.42M | $8.16B |
Volume | 40,287 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $59.06 |
52-Week Low | $3.88 | $26.94 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $79.39M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRTS trades at $8.51, down 2.13% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats but remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, though net losses improved in recent quarters. Analyst sentiment is positive with 60% buy ratings.
The outlook balances technical strength against fundamental challenges. While the stock shows bullish momentum and analyst support, persistent losses and declining revenue pose significant risks. Investment opportunity exists if the company can stabilize revenue and achieve profitability, but current financial performance warrants caution despite positive earnings surprises.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
